AI assistant
Sending…
NEKTAR THERAPEUTICS — Director's Dealing 2023
Dec 16, 2023
32134_dirs_2023-12-15_74b55c45-4919-4053-8068-a5cba4dea3e3.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2023-12-13
Reporting Person: ROBIN HOWARD W (Director, President & CEO)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2023-12-13 | Stock Option | $0.50 | A | 1300000 | Acquired | 2031-12-12 | Common Stock (1300000) | Direct |
Footnotes
F1: This stock option vests over three years from the date of grant, (December 13, 2023) in equal monthly installments based on continued service.
More from NEKTAR THERAPEUTICS
Declaration of Voting Results & Voting Rights Announcements
2026
Jun 5
Capital/Financing Update
2026
May 8
Annual Report
2026
Apr 24
Capital/Financing Update
2026
Apr 23
Capital/Financing Update
2026
Apr 23
Capital/Financing Update
2026
Apr 20
Regulatory Filings
2026
Apr 20
Regulatory Filings
2026
Apr 20
Major Shareholding Notification
2026
Mar 27
Director's Dealing
2026
Feb 20